smoking cessation

Smart-T Digital Intervention Enhances Smoking Cessation Among Low-Income Adults: Insights from a Randomized Clinical Trial

By MedXY 09/11/2025

The Smart-T smartphone intervention significantly improves 7-day smoking abstinence at 26 weeks in low-income adults, outperforming the standard QuitGuide app when combined with nicotine replacement therapy.

Clinical Updates Wellness & Lifestyle

Optimizing Smoking Cessation in Major Depressive Disorder: Varenicline Outperforms Bupropion and Nicotine Patch with Comparable Safety

By MedXY 08/28/2025

This analysis reveals that varenicline is the most effective and safe pharmacotherapy for smoking cessation in individuals with current or past major depressive disorder, outperforming bupropion and nicotine patches with no increased neuropsychiatric risks.

Clinical Updates Wellness & Lifestyle

Cytisinicline’s Promise in Smoking Cessation: Insights from the ORCA Phase 3 Replication Trial

By MedXY 08/25/2025

The ORCA-3 trial confirms cytisinicline's efficacy and safety for smoking cessation at 6 and 12 weeks, showing sustained abstinence and reduced nicotine craving up to 24 weeks.

Clinical Updates Wellness & Lifestyle

Esketamine in Lung Cancer Patients with Major Depression: Efficacy for Smoking Cessation and Treatment-Resistant Depression

By MedXY 08/25/2025

This review synthesizes evidence from a randomized trial and real-world studies showing esketamine's efficacy and safety in smoking cessation among lung cancer patients with MDD, as well as in treatment-resistant depression, highlighting cognitive benefits and long-term safety.

Clinical Updates Wellness & Lifestyle

E-cigarettes versus Combination Nicotine Replacement Therapy for Smoking Cessation in Substance Use Disorder Patients: Integrative Analysis of Recent Trials and Longitudinal Patterns

By MedXY 08/02/2025

Recent trials show no significant difference in smoking cessation rates between e-cigarettes and combination nicotine replacement therapy among patients discharged from inpatient substance use withdrawal services. Longitudinal analyses reveal variable abstinence trajectories in e-cigarette trials, underscoring the need for further relapse-focused research.